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Abstract: Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible 
contraception, and are the most widely used reversible contraceptive method worldwide. The 
levonorgestrel-releasing intrauterine system (LNG-IUS) is a T-shaped IUD with a steroid res-
ervoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 µg daily. It is 
highly effective, with a typical-use first year pregnancy rate of 0.1% – similar to surgical tubal 
occlusion. It is approved for 5 years of contraceptive use, and there is evidence that it can be 
effective for up to 7 years of continuous use. After removal, there is rapid return to fertility, 
with 1-year life-table pregnancy rates of 89 per 100 for women less than 30 years of age. Most 
users experience a dramatic reduction in menstrual bleeding, and about 15% to 20% of women 
become amenorrheic 1 year after insertion. The device’s strong local effects on the endometrium 
benefit women with various benign gynecological conditions such as menorrhagia, dysmenor-
rhea, leiomyomata, adenomyosis, and endometriosis. There is also evidence to support its role 
in endometrial protection during postmenopausal estrogen replacement therapy, and in the 
treatment of endometrial hyperplasia.
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Introduction
Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible 
contraception and are the most widely used reversible contraceptive method world-
wide.1 The levonorgestrel intrauterine system (LNG-IUS) is marketed under the brand 
name Mirena® (Bayer HealthCare), and in some European countries as Levonova®. It 
was first introduced in Finland in 1990, and has since been approved for use in over 
100 countries2 and has over 10 million users.3
In 2007, IUDs were used by 16% of women worldwide aged 15 to 49 who are 
married or in a union.4 They were most commonly used in Asia, with over 40% of 
women using an IUD in China, the Democratic People’s Republic of Korea, Kazakhstan 
and Uzbekistan. Between 30% to 39% of women used IUDs in Israel, Krygyzstan, 
Mongolia, Turkmenistan and Vietnam. This is in contrast to 14% overall use in Europe, 
with 21% in Eastern Europe, 10% in Northern Europe and only 6% in Southern Europe. 
Estimated use is considerably lower in the United States, at only 1.8% of women.
This wide variation in IUD use reflects different patterns of availability, clinician 
and patient perceptions, and cultural influences. Concerns about pelvic inflammatory 
disease (PID) and possible infertility were related to complications with the 
Dalkon Shield from the 1970s, and have been disproved in regard to modern IUDs, 
including the LNG-IUS and copper T380A IUD.6 Because of the growing evidence International Journal of Women’s Health 2009:1 46
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of their safety and efficacy,5–8 and the non-contraceptive 
therapeutic benefits of the LNG-IUS, IUDs are undergoing 
a renaissance in Europe, the United States and elsewhere. 
In addition, liberalization of previously over restrictive 
labeling and medical protocols, including the United States 
Food and Drug Administration (FDA) product labeling, 
has helped to encourage more widespread use of IUDs in 
recent years.9 This article provides an overview of the wide 
range of contraceptive and non-contraceptive benefits of 
the LNG-IUS.
The device
The LNG-IUS is a T-shaped polyethylene device that is 
32 mm long and 32 mm wide (Figure 1) – slightly smaller 
than the copper T380A device which is 36 mm long and 
32 mm wide. It is sterilely packaged with a single use inserter. 
A monofilament polyethylene removal thread attached to a 
loop at the base of the stem, allows for identification of the 
device and facilitates removal. The T-body contains barium 
sulfate, which makes it easily visible on X-ray.
The active ingredient, levonorgestrel (LNG), is dispersed 
in a silicone (polydimethylsiloxane) reservoir on the stem. 
This reservoir contains 52 mg of LNG, and is covered 
by a polydimethylsiloxane membrane which allows for a 
controlled release of the hormone over time. The initial 
release rate of approximately 20 µg per day occurs after 
insertion, and gradually decreases to approximately 10 µg 
per day after 5 years of use.10
Pharmacokinetics
Although the mechanism of action of the LNG-IUS is primarily 
local, the LNG that is released within the uterus is swiftly 
absorbed into the systemic circulation. Maximum plasma 
levels are reached within a few hours after LNG-IUS insertion 
and plateau at 150 to 200 pg/mL (0.4 to 0.6 nmol/L) within 
the first few weeks.10 This is in contrast to the much higher 
plasma hormone levels of combined oral contraceptives, 
progesterone only pills and Norplant® (Figure 2).11 Plasma 
LNG levels from the LNG-IUS remain quite stable over time, 
but there is marked variation between individuals.12,13
Changes in endometrial morphology
In contrast to the relatively low plasma levels, the LNG-IUS 
achieves high concentrations of LNG in the endometrium and 
adjacent tissues. A small study that examined tissue concen-
trations found the average level of LNG in the endometrium 
to be approximately 808 ng/g in users of a prototype LNG-
IUS that released 30 µg /day compared with 3.5 ng/g in a 
group of women taking oral contraceptive pills containing 
250 µg LNG.14 This allows the LNG-IUS to have profound 
endometrial effects that lead to the suppression of endo-
metrial growth. Within 2 to 3 weeks after insertion, local 
LNG concentrations lead to decidualization of the stroma, 
mucosal thinning and an inactive endometrium.15 A foreign 
body reaction is characterized by an increase in inflam-
matory cells including neutrophils, lymphocytes, plasma 
cells and macrophages.16 These endometrial changes are 
finalized within 3 months after insertion of the LNG-IUS,16 
and no further microscopic changes are identified within the 
endometrium thereafter.17 The sequence of these endometrial 
changes influences and explains the why the initial irregular 
bleeding pattern improves with time in most users.
effects on the ovary and pituitary
The ovarian response to the LNG-IUS is directly depen-
dent upon serum LNG levels. More than 50 µg must be 
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Figure 1 The levonorgestrel-releasing intrauterine system device.International Journal of Women’s Health 2009:1 47
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released daily for complete suppression of ovulation, while 
the LNG-IUS releases a maximum of 20 µg per day.18 
Serum LNG levels are highly variable between individuals, 
so ovulation is inhibited only in some women. After LNG-
IUS insertion, anovulatory cycles have been seen in 5% to 
15% of cycles, and correlate with higher circulating levels 
of LNG.19 These effects occur mostly during the first year 
of use, after which, the majority of cycles are ovulatory.20 
Plasma estradiol (E2) and progesterone measurements are 
comparable to those of normally ovulating women.19
LNG-IUS for contraception
Contraceptive mechanisms of action
The contraceptive ability of the LNG-IUS comes from 
the local effects of LNG within the uterine cavity that 
primarily prevent fertilization. A common misconception, 
however, is that the primary mechanism of action of IUDs is 
abortifacient. As this concern represents a barrier to the use 
or recommendation of IUDs by some women and health care 
providers, the issue deserves thorough exploration.
Although interference with implantation plays a role 
in the postcoital effectiveness of copper IUDs, the avail-
able evidence suggests that this is not the mechanism in 
women using IUDs continuously.21 All IUDs produce a 
sterile foreign body reaction within the uterine cavity, 
which creates a hostile environment for sperm.22 The 
LNG-IUS thickens the cervical mucus (interfering with 
sperm passage),23 and inhibits sperm motility and func-
tion inside the uterus and the fallopian tubes (preventing 
fertilization).24 In addition, the LNG-IUS induces expres-
sion of glycodelin A (anendometrial glycoprotein that 
inhibits sperm–egg binding) during the otherwise fertile 
midcycle, when this protein is normally absent.25 Studies 
on the recovery of eggs from women using IUDs compared 
with women using no method of contraception showed that 
normal fertilization did not occur in IUD users.21
These data show that contraceptive efficacy is related 
to preconceptual mechanisms, not implantation disruption. 
It can be concluded that when the rare normal fertilization 
does occur in a LNG-IUS user, it is associated with method 
failure.
Efficacy of LNG-IUS for contraception
Compared to other reversible methods, the LNG-IUS is 
among the most effective with a failure rate of 0.1% in the 
first year – similar to or even better than female sterilization 
(Figure 3).26 It is approved for 5 years of contraceptive use, 
and there is evidence that it can be effective for up to 7 years 
of continuous use.
In 2004 in a large retrospective study that was conducted 
in 17,360 Finnish women who used the LNG-IUS, all 
reported pregnancies were analyzed over 5 years (giving a 
total exposure of 58,600 woman-years). Sixty-four pregnan-
cies occurred, which provided a cumulative pregnancy rate of 
0.1% at 1 year and of 0.5% at 5 years.27 A Cochrane Review 
that evaluated 21 randomized controlled trials concluded that 
the effectiveness of the LNG-IUS is similar to copper IUDs 
with copper surface 250 mm2, and significantly higher than 
IUDs with a copper surface of 250 mm2.28 There is also the 
suggestion that the LNG-IUS may be more effective than the 
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Figure 2 Comparison of plasma concentrations of different contraceptives containing levonorgestrel (LNG). From data of Nilsson et al11 and Diaz et al.12
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copper T380A; however, no randomized controlled trials 
have directly compared these IUDs long term.
The endometrial suppression has been observed up to 
7 years after insertion,29 however the effect on cervical mucus 
may diminish after 5 years of use.30 Nonetheless, contracep-
tive efficacy appears to remain intact with up to 7 years 
of continuous use. In 1991, in a randomized multicenter 
study that was conducted in 2244 women, the cumulative 
pregnancy rate after 7 years of use was 1.1% for the levo-
norgestrel IUD and 1.4% for the copper T380A device.31 
Two other studies that prospectively followed women using 
a LNG-IUS for 7 years reported no pregnancies, one among 
293 women in Brazil,32 and the other among 82 women in 
Sweden.33 While a 1.1% pregnancy rate at 7 years is low 
compared with other reversible methods, this rate is double 
the efficacy achieved at 5 years. Therefore, replacement of 
the LNG-IUS at 5 years is recommended for women desiring 
continuing optimal contraception.
In addition, efficacy does not appear to be related 
to patient age. Other contraceptives, including other IUDs, 
have reported higher failure rates in younger women, mostly 
related to higher fertility rates with younger age. However, 
data indicate that this is not the case with the LNG-IUS 
– women can enjoy the same high contraceptive efficacy 
throughout their reproductive years. 34
return to fertility
The contraceptive actions of the LNG-IUS reverse soon after 
removal of the device. One-year life-table pregnancy rates 
after removal are 89 per 100 for women less than 30 years 
of age – rates are similar to women who had not been using 
any form of birth control.35–37
Acceptability
IUD users report higher satisfaction than users of other 
methods. Overall, 99% of IUD users who continue with 
the method beyond 1 year report being “very satisfied” or 
“somewhat satisfied” with the method.38
Because most women using the LNG-IUS experience 
changes in menstrual bleeding patterns, long-term satis-
faction requires that users find these menstrual changes 
acceptable or desirable. Removal rates attributed to bleed-
ing irregularities or amenorrhea have varied greatly among 
study populations, with differing counseling quality as 
one contributing factor.33 Thorough counseling about 
expected changes in bleeding patterns before IUD insertion 
correlates with satisfaction and continuation rates after 
1 year of use.39
A Finnish survey of over 16,000 women using the 
LNG-IUS found high continuation rates at 1 to 5 years: 93%, 
87%, 81%, 75% and 65%, respectively. Rates were lowest for 
the 18- to 32-year age group and highest for the 39- to 48-year 
age group.40 Risk of premature removal was most strongly 
associated with excessive bleeding and spotting. It was 
also significantly related to symptoms of pelvic infection, 
depression, abdominal pain, and recurrent vaginal infection. 
In contrast, there was a significantly lower risk of removal 
among those who had occasional or no menstruation.
Studies in Brazil report a 90% satisfaction with the 
LNG-IUS,41 and 78% continuation at 1 year.42 In a survey 
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of approximately 500 US women, satisfaction with 
clinician counseling and written product information was 
directly related to the length of LNG-IUS continuation at 
12 months.43 This study also evaluated overall satisfac-
tion with the LNG-IUS on a 7 point scale. The majority of 
women, 84.5%, indicated a level or satisfaction with a value 
of 6 or 7, while only 3.8% indicated low satisfaction, with 
a value of 1 or 2. The most frequently reported reasons for 
liking the LNG-IUS were ease of use, reliability for birth 
control and increasingly lighter menstrual periods (reported 
by 29.9%, 29.2% and 21.8% of subjects, respectively). The 
most frequently reported reasons for disliking the LNG-IUS 
were “nothing,” “other” and the “increase in spotting between 
periods;” these were reported by 46.2%, 12.7% and 12.1% 
of the subjects, respectively. Specific reasons included in the 
“other” category were cramping, spotting or bleeding, felt 
during intercourse by partner or subject, insertion procedure, 
and shortening or absence of menstrual periods.
Potential barriers to use  
of LNG-IUS
Pelvic inflammatory disease (PID)  
and infertility
One of the most persistent questions about IUDs is whether 
they increase the risk of PID. Overall, the rates of PID in 
the few available randomized control trials of IUDs do not 
exceed estimates for the general population.44 Combined 
data from 13 WHO clinical trials conducted in Africa, the 
Americas, Asia, and Europe found that the risk of develop-
ing PID was 6.3 times greater during the first 20 days after 
IUD insertion than at any later time.45 After the first 20 days 
from insertion, the number of new PID cases occurring each 
year remained at a fairly constant low level, approximately 
1.4 per 1000 woman-years, throughout 8 years of use. This 
low level is similar to or even lower than that among women 
in developed countries who do not use IUDs.46,47 In addition, 
some studies have suggested that the LNG-IUS may actually 
protect against upper genital tract infection,34,48 perhaps 
by thickening cervical mucus. A comparative study of the 
LNG-IUS versus the Nova-T copper IUD noted significantly 
lower rates of PID among LNG-IUS users at 3 and 5 years 
of follow-up.48 A second trial comparing the LNG-IUS and 
the copper T 380A IUD showed low terminations rates for 
PID/endometritis (0.7 per 100 years) with both devices.49
The polymicrobial nature of these early infections suggests 
that most occur due to contamination of the uterine cavity with 
endogenous flora during insertion. In addition, women with 
pre-existing asymptomatic chlamydia or gonorrhea have a higher 
risk of PID immediately after IUD insertion.50 Recommended 
steps to lower the risk of insertion related infection include 
careful screening and the use of multi-year devices (fewer 
insertions). Randomized trials of women at low risk for sexu-
ally transmitted infections have found no benefit of empiric 
antibiotic prophylaxis in reducing this insertion-associated risk.51 
The role of sexually transmitted pathogens in later infections is 
independent of the device. In most cases of PID, treatment can 
be administered without removal of the device.52,53
Further reassurance of safety comes from a landmark 2001 
case control study in nulliparous women who were seeking 
treatment for primary infertility that found no association 
between tubal infertility and past IUD use.54 In this study, 
358 women with primary infertility who had documented 
tubal occlusion were compared with two control groups: 
953 nulliparous women with primary infertility and no tubal 
occlusion (infertile controls), and 584 primigravid women (preg-
nant controls). Women with tubal occlusion reported prior IUD 
use at the same rate as infertile women without tubal occlusion 
or primigravid controls. Tubal infertility was associated with 
past chlamydia infection (as evidenced by chlamydia antibodies) 
and not with IUD use. This study supports the association 
between PID and infertility, and not IUD use and infertility.
ectopic pregnancy
Considerable misunderstanding exists over the relationship 
between IUDs and ectopic pregnancy. Although the 
predominant mechanism for medicated IUDs is precon-
ceptual, when fertilization does occur intrauterine effects 
or factors related to tubal transport may discourage normal 
implantation. For this reason, a disproportionate number of 
failures resulting in clinical pregnancies will be ectopics. 
However, the absolute number of ectopic pregnancies is 
lower among IUD users compared to non-contraceptors, 
because the overall pregnancy rate in IUD users is lower. In 
an evaluation of 17,360 women using the LNG-IUS (total 
exposure 58,600 woman-years), 108 reported a pregnancy, 
with 44 of these pregnancies found to be ectopic.40 An 
analysis of 42 randomized trials estimated ectopic rates per 
1000 woman-years to be 0.5 for copper IUDs and 0.2 for the 
LNG-IUS,55 compared with 1.2 to 1.6 per 100 woman-years 
for the control population of sexually active women not using 
contraception.34 Importantly, past or prolonged use of an IUD 
does not increase risk of ectopic pregnancy.56
Since the evidence shows that both copper T380A and 
LNG-IUS users enjoy a substantial reduction in the overall 
risk of both ectopic and intrauterine pregnancy, they both International Journal of Women’s Health 2009:1 50
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should be considered appropriate choices for contraception 
in women with a history of a prior ectopic. Keeping in line 
with this information, restrictive labeling listing a history 
of ectopic pregnancy as a contraindication to use of the 
device was removed from the US package insert of the 
LNG-IUS in 2008.10
Perforation
Perforation is a rare, but recognized potential complication 
of IUD use. It is estimated to occur at a frequency of 0 to 
1.3 per 1000 insertions.57 If a perforation does occur and 
the device is within the peritoneal cavity, the manufacturer 
of the LNG-IUS recommends removal.10 If perforation is 
suspected at the time of insertion (difficult insertion, unusual 
heavy bleeding), the device should be immediately retrieved 
using the removal threads; most cases are asymptomatic 
and surgical exploration or hospitalization is not required. 
If the removal threads are not accessible, or if the 
perforation is recognized later, laparoscopy is the preferred 
surgical approach to removal. Perforation should always 
be considered in the differential for a patient that presents 
with a history of IUD placement, but no device present in 
the uterus on ultrasound exam. An abdominal X-ray can 
confirm the diagnosis. Surgical removal is not an emergency 
in the asymptomatic patient, but should be performed when 
convenient, as a benign natural history for an intrabdominal 
IUD cannot be assumed. A history of a perforation does not 
preclude later use of an IUD, but clinicians should allow 4 to 
6 weeks for healing of the uterine wound, and ultrasound 
should be used to verify correct placement.
There have been 36 reports of fetal exposure to the 
LNG-IUS, 34 with intrauterine exposure and 2 with 
intraperitoneal exposure.58 Two of the 36 infants had congenital 
anomalies – one had a hypoplastic pulmonary artery, and the 
second had cystic hypoplastic kidneys. There is no indication 
that these two anomalies were related to exposure to levonorg-
estrel or to the physical device within the uterine cavity.
Patient selection
WHO Medical Eligibility Criteria (MEC) guidelines report 
few contraindications to IUD use, and suggest that most 
women can safely use the LNG-IUS (Table 1).5 Anyone at 
high risk for sexually transmitted infections (STIs) should be 
screened prior to or at the time of IUD insertion. Anyone not in 
a mutually monogamous relationship should utilize condoms 
for STI prevention in addition to the IUD for contraception.
A past history of PID in a woman with no current risk 
factors for STIs is not a contraindication to use. It is important 
to point out, however, that a prior episode of PID is associated 
with a 15% incidence of infertility.47 Future difficulty with 
pregnancy should not be attributed to the device. IUD inser-
tion should be postponed for at least 3 months after an episode 
of PID or cervicitis, and negative cervical screening tests for 
gonorrhea and chlamydia should be obtained in that situation 
prior to insertion.
Although nulliparity was specifically removed as 
a contraindication from the US FDA labeling of the copper 
T380A in 2005, confusion exists around the language in 
the LNG-IUS package insert. The US LNG-IUS labeling 
was revised in 2008.10 Under indications and usage, it states 
that “Mirena is recommended for women who have had 
at least one child.” However, nulliparity is not listed as a 
contraindication to use of the LNG-IUS in the package insert. 
Clinicians should be guided by the opinion of most experts 
and the WHO MEC that nulliparity is not a contraindication to 
use of either device.5,59 Nulliparous women may have higher 
Table 1 WHO medical eligibility criteria contraindications to levonorgestrel-releasing intrauterine system insertion
(Category 4 or risk is unacceptable)
•  Current pregnancy
•  Current purulent cervicitis or pelvic infection (delay insertion until treatment is complete)
•  Immediate post-septic abortion
•  Current malignant gestational trophoblastic disease
•  Current breast cancer
•  Untreated cervical cancer
•  Untreated endometrial cancer
•  Unexplained vaginal bleeding
•  Distorted uterine cavity (any congenital or acquired abnormality interfering with IUD insertion, including uterine fibroids)
•  Known pelvic tuberculosis
Data from World Health Organization 2004.5International Journal of Women’s Health 2009:1 51
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rates of expulsion, bleeding and pain – probably related to 
uterine size.60 Small uterine size and a tight cervical canal 
may also make insertion more difficult. Still, the advantages 
of IUD use make it an appropriate choice for many nullipa-
rous women.
Undiagnosed genital bleeding should be fully worked 
up prior to IUD insertion. Anatomic features that distort the 
uterine cavity, such as leiomyomata or Mullerian anomalies 
can increase expulsion or bleeding or make placement 
difficult.
Women who have illnesses that result in a serious 
immunocompromised state should be carefully monitored for 
infection if they choose to use an IUD. The risk of pregnancy 
should be weighed against the theoretical risk of infection. 
Data indicate that the IUD can safely be used in HIV-infected 
women who have access to medical care. IUD use is a 
WHO level 2 recommendation (benefit generally outweighs 
risks) for those at high risk for HIV, and for HIV-infected 
or AIDs patients clinically stable on antiretroviral therapy.5 
LNG-IUS use provides the same general benefits as for 
immunocompetent women,61 and does not appear to have any 
drug interactions with antiretroviral therapies.62 In addition, 
IUD use in treated HIV patients does not appear to result 
in an increased risk in overall complications or infections 
beyond the insertion interval.63 It is a WHO level 3 recom-
mendation (risk generally outweighs benefits) to insert an 
IUD in a patient with untreated AIDS.5
Women with diabetes also may safely use an IUD.5 No 
increased risk of infection or other complications have been 
observed. The LNG-IUS provides an attractive alternative 
to systemic hormonal methods, particularly in diabetics 
with vascular disease, smokers, and women with a history 
of thrombosis.
Women with thrombophilia or coagulopathies represent 
other important groups that can benefit from use of the LNG-
IUS.5 In general, the risk of pregnancy due to less effective 
contraception represents a much greater risk of thrombosis 
than use of LNG alone.64 Women with coagulopathies, 
including those on warfarin, experience a reduction in bleed-
ing with the LNG-IUS.65
Insertion timing
In non-pregnant women, IUDs can be inserted during any 
phase of the menstrual cycle.66 Traditionally, physicians felt 
that it was best to insert an IUD either during or just after 
menstruation to ensure that the woman was not pregnant. 
However, limiting insertion to menses creates a barrier to 
IUD use. To maximize flexibility in scheduling and reduce 
the risk of luteal phase pregnancy that may not be detected 
by a sensitive urine pregnancy test, insertion of a LNG-IUS 
can occur anytime during the first half of the menstrual cycle 
in women not currently using contraception. Another option 
is that the patient may abstain from sex for at least 2 weeks 
prior to insertion to ensure that a luteal phase pregnancy will 
not be missed. There is no evidence that the LNG-IUS can 
be effective as emergency contraception, and it should not 
be used in this capacity.
Interestingly, insertion of a T-shaped IUD during the 
middle of the menstrual cycle has been shown to result in 
higher IUD continuation than menstrual insertion. A CDC 
review of more than 9000 T-200 IUD insertions showed 
that insertion from day 12 through 17 of the menstrual cycle 
(mid-cycle) resulted in fewer removals for expulsion, pain, 
bleeding, or unintended pregnancy during the first 2 months 
after IUD insertion.67 Since it takes a few days for the LNG-
IUS contraceptive effects to become established, patients 
should be cautioned to use a back-up method or remain 
abstinent for at least 7 days after midcycle placement.
Immediate insertion after vaginal delivery, cesarean 
section, or abortion also can be a safe option for women. 
With an experienced provider, immediate insertion following 
first trimester abortion has a reported expulsion rate of 5% 
to 8%68,69 compared to interval insertion expulsion rates of 
4% to 5%.70,71 There are less data about insertion immedi-
ately after second trimester abortion, but there appears to be 
a somewhat higher expulsion rate than with first trimester 
abortion insertion.72 Studies are ongoing to evaluate the 
use of the LNG-IUS in this setting. After term delivery or 
cesarean section, the expulsion rate is approximately 12% to 
15% when the IUD is placed within 10 to 30 minutes after 
delivery of the placenta.73,74 An IUD can be inserted at any 
time after a first trimester abortion, but should be delayed 
until after full uterine involution following a second trimester 
procedure, approximately 2 to 3 weeks.5 Postpartum insertion 
may be performed anytime after 4 weeks.5
Insertion technique
All prospective users should be thoroughly counseled 
regarding expected changes in bleeding patterns, and the 
insertion process. Most patients require no premedication 
for IUD insertion. Although the administration of a non-
steroidal anti-inflammatory (NSAID) agent such as ibupro-
fen 400 to 800 mg 30 to 60 minutes prior to the procedure 
is common, a large, well-designed randomized controlled 
trial found no benefit.75 Paracervical block may improve 
comfort, particularly with a closed cervix in a young, International Journal of Women’s Health 2009:1 52
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nulliparous woman or if dilation is needed. Recognizing 
that the paracervical block provides no uterine anesthesia, 
the discomfort of the block may outweigh the benefits, espe-
cially in parous women. For this reason, we discourage the 
routine use of paracervical block. Some women may have a 
vasovagal reaction to the passage of an instrument through 
the cervical canal. Paracervical block may be considered 
in patients with a history of a prior vasovagal reaction to 
cervical manipulation.
A Swedish study of 80 nulliparous women showed that 
providers found IUD insertion to be easier with the use 
of 400 µg misoprostol sublingually 1 hour prior to IUD 
insertion.76 However, the majority of insertions in this 
study were rated as “easy,” regardless of misoprostol use. 
Misoprostol may help with difficult IUD insertions, but there 
is no evidence to support its routine use, particularly since 
many women experience side effects with use.76
The package insert provides detailed information about 
insertion technique, and it is recommended that all providers 
undergo insertion training.10 The LNG-IUS has an inserter 
system that draws the arms into the insertion tube when 
the threads are pulled. The product packaging facilitates 
meticulous sterile technique during preparation of the device. 
Thereafter, a no-touch technique should be adopted to ensure 
that the device remains sterile.
The cervix is prepped and the anterior lip is then grasped 
with a tenaculum to straighten the cervical canal. With a 
retroverted uterus, grasping the posterior lip may facilitate 
this step. While most women tolerate the gentle application 
of the tenaculum, if severe pain occurs, the tenaculum is 
removed and local anesthetic can be administered. Sound the 
uterine cavity to determine the correct depth for insertion. 
The LNG-IUS has a small movable guide (flange) to mark 
correct depth along the insertion tube. While applying firm 
downward traction on the tenaculum to straighten the canal, 
pass the insertion tube into the uterine cavity. Take care to 
position the device so that the arms will lie in the horizontal 
plan of the uterus with the tips pointing into the cornual 
regions of the cavity when released. The insertion tube of the 
LNG-IUS is positioned until the flange is about 1.5 to 2 cm 
from the external os. At this point, the arms of the device are 
released from the insertion tube by pulling the slider back 
to a marked position on the insertion tube. After a slight 
delay to allow expansion of the arms, the inserter tube is 
gently pushed into the uterine cavity until the previously set 
flange guide touches the cervix. The LNG-IUS should now 
be at the fundal position, and can be released by pulling the 
slider down all the way. Confirm that the threads are released 
(this should occur automatically) and slowly withdraw the 
insertion tube.
Trim the threads to a length of approximately 3 cm.10 
Err on the side of extra tail length as the threads may always 
be trimmed later if they are too long. Long threads usually 
curl around the cervix into the fornices. Short threads tend 
to stick out from the os along the long axis of the cervix and 
may result in dyspareunia for the male partner.
Expected changes in bleeding and warning signs of infec-
tion or expulsion should be reviewed with all patients after 
insertion. Follow-up within the next month after insertion is 
not necessary for all patients – this can be individualized as 
needed. A follow-up appointment can allow for identification 
of expulsion or infection. It also can provide an opportunity 
for additional counseling about changes in bleeding, or 
other concerns which might result in premature removal 
of the device. While not recommended for all insertions, 
selective use of ultrasound following difficult insertions 
or in training settings can confirm correct placement of the 
device (Figure 4).
Non-contraceptive uses of LNG-IUS
While millions of women worldwide enjoy the contraceptive 
protection of the LNG-IUS, the non-contraceptive benefits 
of the system present unique opportunities for treatment 
of a variety of gynecologic problems in symptomatic 
patients with or without contraceptive needs. The health 
benefits of systemic hormonal contraception are well 
established.77 However, some women have contraindica-
tions to the use of estrogen, and not all women tolerate 
systemic progestin therapy. The LNG-IUS offers many of 
the same health benefits seen in users of systemic hormonal 
contraception – reduction in menstrual flow, dysmenorrhea, 
and pelvic pain symptoms. With the unique local delivery 
system of the LNG-IUS, LNG is released directly into the 
uterine cavity with low systemic levels. For most patients, 
this translates into fewer hormone-related symptoms.34 
Currently, all non-contraceptive use of LNG-IUS is off-label 
in the US, but several of these uses are common approved 
indications in many other countries.
Changes in bleeding patterns
Use of the LNG-IUS results in endometrial thinning, glandular 
atrophy, stromal decidualization.17 During this process, spotting 
occurs frequently during the initial 4 to 6 cycles. However, 
after this transition, most women with normal menstrual cycles 
enjoy a reduction in both the number of menstrual bleeding 
days and the amount of objectively measured menstrual blood International Journal of Women’s Health 2009:1 53
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loss.78 Amenorrhea occurs in 15% to 20% of LNG-IUS users 
during the first year of use, and increases to 30% to 40% with 
longer durations of use.49,79 This is a desirable attribute for 
many women worldwide, even if eliminating their menses is 
more for convenience than to treat a gynecologic disorder.80
Menorrhagia
The LNG-IUS is approved in over 100 countries for the 
treatment of menorrhagia.81 It has been shown to outperform 
other hormonal and non-hormonal medical treatment options.82,83 
A study of 34 Chinese women who failed conventional therapy 
for menorrhagia showed a 98% reduction in average menstrual 
blood loss 2 years after insertion of a LNG-IUS. Significantly, 
this improvement occurred early, with approximately one third 
of the women reporting amenorrhea by 6 months.84
In addition, a number of studies support LNG-IUS use 
as an effective, conservative treatment option that preserves 
reproductive function and avoids surgical risks and costs. 
A Finnish 5-year study comparing women with menorrhagia 
randomized to LNG-IUS or hysterectomy found similar 
B
A
Figure 4 The levonorgestrel-releasing intrauterine system can be easily identified on transvaginal ultrasound. Note the shadowing caused by the stem of the device (arrows) 
in the anterior-posterior plane (panel A), and the T bar seen in the transverse orientation (panel B).International Journal of Women’s Health 2009:1 54
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measures of satisfaction and quality of life between treatment 
groups, and significantly lower costs in the LNG-IUS group.85 
Comparisons of the LNG-IUS with endometrial resection 
or thermal balloon ablation have shown that both treatment 
options provide significant reduction in bleeding and similar 
patient satisfaction.86,87 A recent Cochrane review included five 
randomized trials directly comparing ablation to LNG-IUS 
for management of menorrhagia.87 Of these, two showed 
better controlled bleeding at 1 year with ablation,87,88 and 
three showed no difference in bleeding control at 1 to 3 years 
between these two options. A subsequent randomized trial of 
83 women in New Zealand showed a better bleeding profile 
with LNG-IUS after 2 years compared to balloon ablation.89 
All studies that have evaluated cost of surgical treatments 
compared to LNG-IUS have shown that the LNG-IUS is 
more cost-effective.87
Anemia
Since excessive menstrual bleeding is a common cause of anemia 
in fertile women, the profound reduction in bleeding associated 
with LNG-IUS use not surprisingly results in sustained 
increases in hemoglobin, hematocrit, and serum ferritin.33 
Long-term follow-up studies of LNG-IUS in healthy women 
have demonstrated favorable sustained increased from baseline 
in hemoglobin concentrations with a mean increase of 1.6 g/dL 
after 5 years of use90 and 1.44 g/dL after 7 years of use.31
endometrial protection during  
hormone replacement
Use of the LNG-IUS provides endometrial protection in 
women receiving estrogen replacement therapy, and is an 
approved indication of the LNG-IUS in over 90 countries.81 
In a randomized study of 40 perimenopausal women who 
received oral estradiol 2 mg and either a LNG-IUS or 
levonorgestrel 250 µg orally for the last 10 days of the cycle,91 
bleeding disturbances gradually diminished in the LNG-IUS 
group, and 83% of women were amenorrheic by 12 months. 
No endometrial proliferation or atypia was apparent in any of 
the biopsy samples from either group. These favorable findings 
were corroborated by studies using the LNG-IUS in conjunc-
tion with sustained-release subdermal92,93 transdermal,94 and 
oral91 estrogen delivery systems with 1 to 3 years of follow-up. 
Three further trials have reported the sustained endometrial 
protection effects of the LNG-IUS over 5 years.95–97
Uterine myoma
The LNG-IUS has been shown to reduce blood loss associated 
with fibroids, however there is less consistent data about its 
ability to reduce the size of fibroids or overall uterine dimen-
sions.98 In a Russian study of 67 women with myomas, uterine 
size of 12 weeks, and a normal uterine cavity, the LNG-IUS 
substantially reduced blood loss at 12 months, and decreased 
uterine and leimyomata size.99 Forty percent of these women 
were amenorrheic by 12 months, and all but 1 woman had 
hemoglobin concentrations of 12 g/dL by 12 months. 
A Turkish study enrolled 32 women with menorrhagia, at 
least one submucosal fibroid 50% into the uterine cavity, 
and overall uterine volume 380 mL to receive a LNG-IUS.100 
These subjects were followed for 12 months, and bleeding and 
hemoglobin levels were compared to 32 historical controls who 
underwent thermal balloon ablation. There was significant and 
similar improvement in bleeding and hemoglobin levels in both 
groups, and no changes in uterine volume or fibroid sizes.
There is also evidence of a potential preventive effect. 
Among women randomized to treatment with either the 
LNG-IUS or copper T380A, the incidence over 7 years of a 
new diagnosis of uterine myoma or myoma-related surgery 
was significantly lower in the LNG-IUS group.49
Treatment of pelvic pain associated 
endometriosis and adenomyosis
Several small pilot studies suggest that the LNG-IUS can 
be useful in the treatment of pelvic pain associated with 
endometriosis and adenomyosis.101–108 Two studies that 
evaluated postoperative insertion of a LNG-IUS resulted in 
a significant reduction in the symptoms of dysmenorrhea 
in women treated with laparoscopy for endometriosis.102,103 
Another randomized study found that the improvement in 
pain and quality of life achieved in women with endometriosis 
with the LNG-IUS is comparable to that achieved with a 
GnRH agonist, even with Stage III/IV disease.104
Successful management of pain and abnormal bleeding 
associated with adenomyosis has also been reported.105,106 
A Brazilian study of 29 women with adenomyosis showed a 
reduction in junctional zone thickness between endometrium 
and myometrium by magnetic resonance imaging (MRI), but 
no decrease in uterine volume.107 A recent Chinese study 
showed effectiveness in treating adenomyosis with 3 years 
of continuous use.108
Treatment of endometrial hyperplasia  
and cancer
A number of studies consistently have shown a decreased risk of 
endometrial cancer in IUD users compared to nonusers, however 
most studies did not specify the IUD types being investigated.109 International Journal of Women’s Health 2009:1 55
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A recent meta-analysis found a protective association between 
IUD use and endometrial cancer, with a pooled odds ratio of 
0.54 (95% CI 0.47 to 0.63).110 The mechanism by which copper 
and inert IUDs provide this protection is unclear. However, 
there is biologic plausibility that locally delivered LNG by the 
LNG-IUS would oppose estrogen related endometrial changes 
that lead to hyperplasia and cancer.111 Since systemic progestins 
are poorly tolerated by some patients, local progestin delivery 
can be an attractive alternative.
There is evidence of complete histological regression 
of endometrial hyperplasia with LNG-IUS treatment.112–115 
A recent, non-randomized, Norwegian study compared LNG-
IUS, oral progestins and observation among 370 women with 
simple and atypical hyperplasia. In this study, the LNG-IUS 
showed superior resolution over oral progestins or observa-
tion, and there were no cases that progressed to cancer when 
followed to a maximum of 106 months.116
In women with proven early endometrial cancer, three 
case series have reported treatment with the LNG-IUS. These 
studies, which collectively include a total of 27 women with 
grade 1 endometrial carcinoma, have shown a regression rate 
of  25% to 75% after LNG-IUS exposure.117–119 Further studies 
are needed to determine the utility and safety of LNG-IUS 
for the treatment of endometrial cancer.
Adjuvant therapy with tamoxifen
Tamoxifen stimulates the uterus, and increases the risk of 
endometrial polyps, fibroids, hyperplasia120 and endometrial 
cancer.121 Results from a randomized trial determined that the 
LNG-IUS prevented the development of endometrial polyps 
or hyperplasia in patients receiving tamoxifen over 1 year 
of use.122 However, women who received the LNG-IUS also 
experienced more bleeding. Given the unproven safety of the 
LNG-IUS in breast cancer patients, longer-term randomized 
studies are needed to determine the benefit to risk balance in 
these patients. It is reassuring to note that population-based 
studies have not shown an increase in the risk of breast cancer 
among LNG-IUS users.123
Summary
The wide range of benefits of the LNG-IUS, in both contracep-
tion and treatment of gynecological disorders, will continue 
to make it an attractive option for women worldwide. Its con-
traceptive efficacy is excellent – comparable to, if not higher 
than, surgical sterilization, and it is reversible. In addition, 
it can offer women improvement in anemia, menorrhagia, 
endometriosis, control of uterine fibroids and adenomyosis, and 
protection against and treatment of endometrial hyperplasia 
and possibly early endometrial cancer. Because of its effec-
tiveness, high patient acceptability and demonstrated safety, 
the LNG-IUS will continue to provide important benefits in 
women’s reproductive health.
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